Loading...

Lee Daniel Gibbs

Title(s)Postdoctoral Scholar - Research Associate
Emailleedanig@usc.edu
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Xavier University of Louisiana, New Orleans, LAB.S. 05/2011Biology
    University of North Texas Health Science Center, Fort Worth, TXPh.D. 05/2017Biomedical Sciences

    Collapse Overview 
    Collapse Overview
    Dr. Lee D. Gibbs is a postdoctoral research fellow in the Department of Translational Genomics at Keck School of Medicine of University of Southern California under the mentorship and guidance of Dr. John D. Carpten. He works with a multi-disciplinary team to evaluate genomic alterations that are inherited and acquired during tumor development and to understand the clinical significance of these events. His research focuses on using novel genomic sequencing technologies to reveal the unexplored landscape of tumor heterogeneity spatially and at a single cell resolution. He also applies long-read sequencing technologies to identify novel isoforms to understand the true identity and complexities of oncogenes and tumor suppressors. These technologies will enable the design of precise and personalized therapies. In addition, his research focuses on the discovery and validation of biomarkers and therapeutic targets in rare and aggressive cancers that affect minorities and medically underserved populations. His goal is to evaluate the functional significance of these genomic events and their potential to determine prognosis, diagnosis, and therapeutic response.

    Dr. Gibbs is a scholar in the USC Provost’s Scholars Program for Faculty Diversity. This program enhances the diversity of postdoctoral scholars at the university and builds a pool of exceptional underrepresented minority candidates for the next generation of faculty across higher education. As a scholar, he will link the expertise of USC faculty and doctoral students with the knowledge and unique experiences gained through his research and scholarship. Additionally, he has received the USC Provost’s Postdoctoral Scholar Research Grant for one of his ongoing projects. This project uses Oxford Nanopore Technologies’ MinION, a portable device that is based on single molecule sequencing technology that provides reads of unprecedented length by performing voltage driven molecule translocations through small nanosensors. Oxford Nanopore’s long read sequencing technology to sequence DNA and RNA can lead to recognition of novel biomarkers to enhance detection, treatment, and prognosis. The proposed study will determine the true representation of a disease-specific transcriptome and identify novel tumor-specific isoforms and isoform specific mutations in breast, endometrial, gastric, and ovarian cancers, particularly those affecting diverse populations within the USC Norris Cancer Center catchment area.

    Collapse Research 
    Collapse Research Activities and Funding
    Identification of novel tumor-specific isoforms and isoform-specific mutations using nanopore long-read sequencing technology
    USC Provost’s Postdoctoral Scholar Research Grant Jan 7, 2019 - Jan 7, 2020
    Role: Principal Investigator
    USC Provost’s Scholars Program for Faculty Diversity
    University of Southern California Office of the Provost Sep 30, 2017 - Sep 30, 2019
    Role: Provost's Research Scholar
    Role Description: This program enhances the diversity of postdoctoral scholars at the university and builds a pool of exceptional underrepresented minority candidates for the next generation of faculty across higher education. As a scholar, I will link the expertise of USC faculty and doctoral students with the knowledge and unique experience gained through my research and scholarship.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Gibbs LD, Chaudhary P, Mansheim K, Hare RJ, Mantsch RA, Vishwanatha JK. ANXA2 expression in African American triple-negative breast cancer patients. Breast Cancer Res Treat. 2019 Feb; 174(1):113-120. PMID: 30478786.
      View in: PubMed
    2. Gibbs LD, Vishwanatha JK. Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. Oncotarget. 2018 Jan 05; 9(2):2697-2704. PMID: 29416802.
      View in: PubMed
    3. Rajendiran S, Gibbs LD, Van Treuren T, Klinkebiel DL, Vishwanatha JK. MIEN1 is tightly regulated by SINE Alu methylation in its promoter. Oncotarget. 2016 Oct 04; 7(40):65307-65319. PMID: 27589566.
      View in: PubMed
    4. Kpetemey M, Dasgupta S, Rajendiran S, Das S, Gibbs LD, Shetty P, Gryczynski Z, Vishwanatha JK. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Mol Cancer. 2015 Aug 15; 14:156. PMID: 26272794.
      View in: PubMed
    5. Rajendiran S, Kpetemey M, Maji S, Gibbs LD, Dasgupta S, Mantsch R, Hare RJ, Vishwanatha JK. MIEN1 promotes oral cancer progression and implicates poor overall survival. Cancer Biol Ther. 2015; 16(6):876-85. PMID: 25996585.
      View in: PubMed
    6. Kpetemey M, Kashyap MV, Gibbs L, Vishwanatha JK. Breast cancer disparities: Frontline strategies, proceedings of the 7(th) annual texas conference on health disparities. J Carcinog. 2012; 11:16. PMID: 23230393.
      View in: PubMed